Open Beta
TREN
MetriLume
TREN

US marketsAKBA

SEC-sourced researchBeta

AKBA

Akebia Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001517022
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Aug 10, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 194,623,000.0000 USD; December 2024: 160,180,000.0000 USD; December 2025: 236,196,000.0000 USD236.2M USD0 USD0December 2023December 2024December 2025
AKBA · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2023194,623,000.0000Feb 26, 2026
December 2024160,180,000.0000Feb 26, 2026
December 2025236,196,000.0000Feb 26, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025236,196,000.0000-5,345,000.000067,992,000.0000376,565,000.0000343,955,000.0000Feb 26, 2026
December 2024160,180,000.0000-69,410,000.0000-40,659,000.0000220,670,000.0000269,855,000.0000Feb 26, 2026
December 2023194,623,000.0000-51,925,000.0000-23,384,000.0000——Feb 26, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

70/100
Profitability45
Growth97
Balance sheet9
Cash generation100
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$236.2MJan 1, 2025 – Dec 31, 2025Feb 26, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$160.18MJan 1, 2024 – Dec 31, 2024Feb 26, 202610-K
Net incomeNetIncomeLoss-$5.35MJan 1, 2025 – Dec 31, 2025Feb 26, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$67.99MJan 1, 2025 – Dec 31, 2025Feb 26, 202610-K
Total assetsAssets$376.57MDec 31, 2025Feb 26, 202610-K
Total liabilitiesLiabilities$343.96MDec 31, 2025Feb 26, 202610-K

New filings

Explore methodology ↗